119461-41-5

Upstream product

• 54655-07-1 lithium trimethylsilylacetylenide 
• 119461-40-4 S-(+)-2-methyl-N-p-tosylaziridine 
• 88129-44-6 (S)-N-(p-toluenesulfonyl)-2-amino-1-propyl p-toluenesulfonate 

Downstream Products

• 119461-42-6 (S)-N-(p-toluenesulfonyl)-4-amino-1-Z-(trimethylsilyl)-1-pentene 
• 885104-48-3 (S)-4-methyl-N-(pent-4-yn-2-yl)benzenesulfonamide 
• 119461-54-0 rac-trans-N-(ethoxycarbonyl)-6-methyl-2-phenyl-1,2,5,6-tetrahydropyridine 
• 119461-54-0 rac-cis-N-(ethoxycarbonyl)-6-methyl-2-phenyl-1,2,5,6-tetrahydropyridine 
• 119461-45-9 rac-cis 6-methyl-2-phenyl-1,2,5,6-tetrahydropyridines 
• 119461-45-9 rac-trans 6-methyl-2-phenyl-1,2,5,6-tetrahydropyridines 
• 119461-53-9 (Ethoxy-phenyl-methyl)-((Z)-(S)-1-methyl-4-trimethylsilanyl-but-3-enyl)-carbamic acid ethyl ester 
• 119461-49-3 rac-trans-N-benzyl-6-methyl-2-phenyl-1,2,5,6-tetrahydropyridine 
• 119461-44-8 ((Z)-(S)-1-Methyl-4-trimethylsilanyl-but-3-enyl)-[1-phenyl-meth-(E)-ylidene]-amine 
• 119461-52-8 rac-trans-N-methyl-6-methyl-2-phenyl-1,2,5,6-tetrahydropyridine 

Relevant academic research and scientific papers

NOVEL B1 BRADYKININ RECEPTOR ANTAGONISTS

The invention encompasses novel compounds of a formula I and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for treatment of diseases mediated by B1 bradykinin receptor.

SYNTHESIS OF SUBSTITUTED TETRAHYDROPYRIDINES BY CYCLIZATIONS OF SILICON-CONTAINING IMINIUM IONS

Trans-2,6-disubstituted-1,2,5,6-tetrahydropyridines are formed stereoselectively from the cyclization of silicon-containing iminium cations 5 if the nitrogen substituents R1 is an alkyl group.In contrast, cyclization of the corresponding NH or N-acyl iminium ions occurs in a stereorandom fashion.Nonracemic tetrahydropyridines cannot be prepared in this way, since both iminium ion and N-acyliminium ion intermediates racemize prior to cyclization.